Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 48 entries
View as:

Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01975337 Org: User:
Start: 08/31/13 End: 02/28/14 Due: 02/28/15

A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03209648 Org: User:
Start: 06/14/17 End: 08/31/17 Due: 08/31/18

Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial

Phase: N/A Priority: Normal
NCT ID: NCT02022098 Org: User:
Start: 10/31/13 End: 04/28/22 Due: 04/28/23

Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C

Phase: N/A Priority: Normal
NCT ID: NCT01500772 Org: User:
Start: 03/31/12 End: 05/31/12 Due: 05/31/13

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01860326 Org: User:
Start: 03/31/11 End: 09/30/11 Due: 09/30/12

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

Phase: N/A Priority: Normal
NCT ID: NCT01318694 Org: User:
Start: 03/31/11 End: 08/31/13 Due: 08/31/14

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

Phase: N/A Priority: Normal
NCT ID: NCT03834220 Org: User:
Start: 03/22/19 End: 01/04/22 Due: 01/04/23

A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

Phase: N/A Priority: Normal
NCT ID: NCT00537407 Org: User:
Start: 09/30/07 End: 04/30/10 Due: 04/30/11

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

Phase: N/A Priority: Normal
NCT ID: NCT02753699 Org: User:
Start: 12/31/11 End: 05/31/15 Due: 05/31/16

Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT01078649 Org: User:
Start: 03/29/10 End: 04/30/14 Due: 04/30/15

Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143

Phase: N/A Priority: Normal
NCT ID: NCT04122625 Org: User:
Start: 04/26/19 End: 04/06/22 Due: 04/06/23

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01183169 Org: User:
Start: 08/31/10 End: 05/31/13 Due: 05/31/14

Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01930292 Org: User:
Start: 04/30/13 End: 03/31/16 Due: 03/31/17

A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03270176 Org: User:
Start: 10/10/17 End: 03/22/22 Due: 03/22/23

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01656161 Org: User:
Start: 07/31/12 End: 08/31/13 Due: 08/31/14

A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT07035769 Org: User:
Start: 06/18/25 End: 05/31/26 Due: 05/31/27

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

Phase: N/A Priority: Normal
NCT ID: NCT02094443 Org: User:
Start: 03/31/14 End: 04/30/15 Due: 04/30/16

Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus

Phase: N/A Priority: Normal
NCT ID: NCT03723551 Org: User:
Start: 02/20/19 End: 12/31/26 Due: 12/31/27

A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05109975 Org: User:
Start: 11/05/21 End: 06/30/27 Due: 06/30/28

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)

Phase: N/A Priority: Normal
NCT ID: NCT06129539 Org: User:
Start: 07/31/24 End: 02/29/28 Due: 02/28/29

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06395753 Org: User:
Start: 05/23/24 End: 01/31/27 Due: 01/31/28

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05815160 Org: User:
Start: 05/02/23 End: 04/30/26 Due: 04/30/27

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT05765812 Org: User:
Start: 05/15/23 End: 09/30/28 Due: 09/30/29

Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03968653 Org: User:
Start: 07/30/19 End: 11/30/27 Due: 11/30/28

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05706129 Org: User:
Start: 03/14/23 End: 03/31/29 Due: 03/31/30